Takeda Pharmaceutical's strong earnings, dividends, and strategic moves make it an appealing investment despite US policy uncertainties. Read my earnings analysis.

Meanwhile, a new subcutaneous formulation of Takeda’s Entyvio (vedolizumab) – currently given as an intravenous infusion – was recommended for approval by the EMA as a maintenance therapy in ...

We recently launched Vyalev, the only subcutaneous 24-hour continuous infusion ... a study comparing Skyrizi to Entyvio in ulcerative colitis will be initiated. Additional mid-stage monotherapy ...

It will compete with other biologic therapies for Crohn's, including J&J's IL-12 and IL-23 inhibitor Stelara (ustekinumab), Takeda's Entyvio ... followed by a 360mg subcutaneous shot given ...

The FDA approved subcutaneous Opdivo for solid tumors, providing a more convenient treatment option that reduces time toxicity and enhances patient accessibility. Subcutaneous administration allows ...

The subcutaneous formulation of Opdivo provides a convenient alternative to intravenous administration for patients with solid tumors, maintaining efficacy and safety. The CHECKMATE-67T trial ...

Jeffrey Stewart; Executive Vice President, Chief Commercial Officer; AbbVie Inc Carrie Strom; Senior Vice President, AbbVie and President, Global Allergan Aesthetics; AbbVie Inc Roopal Thakkar; ...

AbbVie provided an optimistic outlook for 2025, with an adjusted EPS guidance range of $12.12 to $12.32 and total net revenues expected to reach $59 billion. The company anticipates significant ...